Psychotropic Medications

About this course

Psychotropic medications are a category of drugs used to treat various mental health disorders and are integral components of effective treatment and long-term therapy This course aims to provide an overview of psychotropic medications, focusing on the five standard classes of drugs extensively used in psychiatric care commonly prescribed medications within the classifications, typical diagnoses, associated side effects, and black box warnings.

Learning objectives

• Review the physiology associated with the neurotransmitter systems within the central nervous system (CNS).
• Review the five common classes of psychotropic medications used to treat mental health conditions, the medications within the classes of psychotropic medications, and their side effects.
• Understand the importance of the black box warning as an alert for significant risk and potentially life threatening adverse reaction when it is issued by the Food and Drug Administration (FDA).
• Identify the black box warnings for medications within the five classes of common psychotropic medications.
• Review nursing considerations for a patient undergoing a treatment regimen for mental health.

Course outline

19 sections · finish in any order across devices

1. 1

   Introduction

   Psychotropic medications are a category of drugs used to treat various mental health disorders. Not only do they offer relief from debilitating symptoms, but they also improve the overall quality of life for millions of individuals worldwide. Despite their once controversial reputation, increased aw

   4 min

2. 2

   Prevalence of Mental Health Disorders

   Mental health disorders are a significant global concern, with one in every eight people worldwide affected.2 Among these disorders, the most prevalent are:3

   4 min

3. 3

   Statistical Data on Psychotropic Medications Use

   In 2020, the prevalence of mental health treatment among adults in the United States saw a notable rise. Approximately 20% of the adult population (age 18 and older) has been prescribed some form of mental health therapy.15 This includes those who have taken prescription medication for their mental

   4 min

4. 4

   Review of the Nervous System

   To understand how psychotropic medications work, it is crucial to grasp the neurotransmitter systems within the central nervous system (CNS). The CNS, the brain and spinal cord, is responsible for processing and transmitting information throughout the body.16 It does so through a complex network of

   4 min

5. 5

   Common Types of Psychotropic Medications

   Psychotropic medications primarily exert their effects on neurotransmitter systems.15 They increase or decrease the concentrations of brain chemicals, either through reuptake inhibition, enzymatic degradation, or direct receptor agonism or antagonism. In reuptake inhibition, medications prevent neur

   4 min

6. 6

   Antianxiety Medications

   Antianxiety medications, also known as anxiolytics, are a category of drugs for treating anxiety disorders, which include generalized anxiety disorders (GADs), panic disorders, social anxiety disorders, and specific phobias.19 These medications primarily target GABA or serotonin levels in the brain

   4 min

7. 7

   Antidepressants

   Antidepressants are primarily used to treat major depressive disorder. However, they have also proven effective in managing other mental health diagnoses, such as obsessive-compulsive disorder (OCD), anxiety disorder, and post-traumatic stress disorder (PTSD).21 The most commonly prescribed classes

   4 min

8. 8

   Antipsychotics

   Antipsychotics are used to manage psychosis, a disassociation from reality. They are also used to treat symptoms of bipolar disorder, schizophrenia, and severe depression with psychotic features. Antipsychotics are categorized into two main classes: 23

   4 min

9. 9

   Mood Stabilizers

   Mood stabilizers are predominantly used to treat mood disorders, particularly bipolar disorder, which is characterized by intense mood swings that oscillate between emotional highs (mania) and lows (depression).24 Mood stabilizers are also used in the treatment of other conditions, such as schizoaff

   4 min

10. 10

    Stimulants

    Stimulants are a class of psychotropic medications primarily prescribed for ADHD and narcolepsy, a sleep disorder marked by excessive daytime sleepiness, sudden episodes of muscle weakness (cataplexy), and disrupted nighttime sleep.27 In some cases, stimulants may be prescribed off-label for other c

    4 min

11. 11

    Importance of Continuing Medications

    Psychotropic medications are essential tools in the treatment of mental health disorders because they directly influence brain chemistry, helping to alleviate symptoms associated with mental health conditions. However, adherence is vital for effective management.28 When patients follow the medicatio

    4 min

12. 12

    Black Box Warnings

    Black box warnings, also referred to as boxed warnings, are the highest warning issued by the FDA for prescription medications.31 Prominently displayed on the package insert or label of a medication, a black box warning is used to alert healthcare providers and patients on the significant risks and

    4 min

13. 13

    Antianxiety Medications

    Benzodiazepines, a class of antianxiety medications, carry significant risks that must be carefully considered. Benzodiazepines are notorious for their potential to cause psychological and physical dependence, even when taken at therapeutic doses and for short periods.32 Prolonged use or high doses

    4 min

14. 14

    Antidepressants

    Antidepressants such as SSRIs and SNRIs carry a black box warning due to their tendency to increase suicidal thoughts and tendencies in children, adolescents, and young adults under the age of 25.34 Studies suggest this may be because individuals are more vulnerable to mood fluctuations caused by th

    4 min

15. 15

    Antipsychotics

    All antipsychotic medications come with a black box warning as they increase the risk of mortality in elderly patients with dementia-related psychosis.35 Clinical studies have shown that these individuals may experience an increased risk of death when treated with antipsychotics, often due to cardio

    4 min

16. 16

    Mood Stabilizers

    The mood stabilizer lithium carries a black box warning because of its risk of lithium toxicity.37 Even though it is a cornerstone treatment for bipolar disorder, lithium's therapeutic range is relatively narrow. This means the difference between a therapeutic and a toxic dose is slight. If not moni

    4 min

17. 17

    Stimulants

    Stimulant medications carry a black box warning because of their high potential for abuse and dependence.39 Their stimulating properties can create a euphoric effect when taken in higher-than-prescribed doses, leading to misuse and addiction. For this reason, stimulants are also classified as Schedu

    4 min

18. 18

    Nursing Considerations

    Given the complex interactions and effects of psychotropic medications, several nursing considerations must be made before including psychotropic medications in treatment plans. Before initiating any medication, it is crucial for nurses to conduct a thorough patient assessment.19 This includes obtai

    4 min

19. 19

    Conclusion

    The importance of psychotropic medications in treating mental health disorders cannot be overstated. By targeting neurotransmitter systems, psychotropic medications aim to restore neurochemical balance, thereby alleviating symptoms to improve the quality of life for those struggling with mental heal

    4 min

This course satisfies

Requirement summaries come from our state requirement records. Always confirm details with your board before you renew.

References and resources

• Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., L Chui, C. S., Hayes, J. F., C Man, K. K., Y Lau, W. C., C Yan, V. K., Beykloo, M. Y., Wang, Z., Wei, L., & K Wong, I. C. (2021). Psychotropic medicine consumption in 65 countries and regions, 2008–19: A longitudinal study. The Lancet. Psychiatry, 8(12), 1071-1082. https://doi.org/10.1016/S2215-0366(21)00292-3
• World Health Organization. (2022, June 8). Mental disorders. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/mental-disorders
• World Health Organization. (2023, September 27). Anxiety Disorders. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders
• National Institute of Mental Health. (n.d.). Any Anxiety Disorder. Www.nimh.nih.gov; National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder
• World Health Organization. (2023, March 31). Depressive disorder (depression). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/depression
• Mental Health America. (2023). Depression. Mental Health America. https://mhanational.org/conditions/depression
• Bipolar disorder. (n.d.). Www.who.int. https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder
• National Institute of Mental Health. (2022). Bipolar Disorder. Www.nimh.nih.gov. https://www.nimh.nih.gov/health/statistics/bipolar-disorder
• Post-traumatic stress disorder. (n.d.). Www.who.int. https://www.who.int/news-room/fact-sheets/detail/post-traumatic-stress-disorder
• National Center for PTSD. (2023, February 3). How Common Is PTSD in Adults? U.S. Department of Veteran Affairs. https://www.ptsd.va.gov/understand/common/common_adults.asp
• Schizophrenia Fact Sheet - Treatment Advocacy Center. (2022, January 1). Www.treatmentadvocacycenter.org. https://www.treatmentadvocacycenter.org/reports_publications/schizophrenia-fact-sheet/
• Conduct Disorder. (n.d.). Yale Medicine. https://www.yalemedicine.org/conditions/conduct-disorder
• Many countries have the same challenges. (n.d.). Health.ucdavis.edu. Retrieved July 10, 2024, from https://health.ucdavis.edu/health-magazine/issues/summer2017/features/challenges.html
• National Institute of Mental Health. (2014). Attention-Deficit/Hyperactivity Disorder (ADHD). Www.nimh.nih.gov; National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/attention-deficit-hyperactivity-disorder-adhd
• Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., L Chui, C. S., Hayes, J. F., C Man, K. K., Y Lau, W. C., C Yan, V. K., Beykloo, M. Y., Wang, Z., Wei, L., & K Wong, I. C. (2021). Psychotropic medicine consumption in 65 countries and regions, 2008–19: A longitudinal study. The Lancet. Psychiatry, 8(12), 1071-1082. https://doi.org/10.1016/S2215-0366(21)00292-3
• The Central Nervous System | SEER Training. (n.d.). Training.seer.cancer.gov. https://training.seer.cancer.gov/anatomy/nervous/organization/cns.html
• National Cancer Institute. (2019). Nerve Tissue | SEER Training. Cancer.gov. https://training.seer.cancer.gov/anatomy/nervous/tissue.html
• Teleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022). Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. International Journal of Molecular Sciences, 23(11), 1–24. https://doi.org/10.3390/ijms23115954
• Altamura, A. C., Moliterno, D., Paletta, S., Maffini, M., Mauri, M. C., & Bareggi, S. (2013). Understanding the pharmacokinetics of anxiolytic drugs. Expert Opinion on Drug Metabolism & Toxicology, 9(4), 423–440. https://doi.org/10.1517/17425255.2013.759209
• Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International, 13(4), 594-607. https://doi.org/10.3390/neurolint13040059
• Braund, T. A., Tillman, G., Palmer, D. M., Gordon, E., Rush, A. J., & F. Harris, A. W. (2021). Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: An iSPOT-D report. Translational Psychiatry, 11. https://doi.org/10.1038/s41398-021-01533-1
• Gutlapalli, S. D., Chaudhuri, D., Khan, K. I., Shouli, R. A., Allakky, A., Ferguson, A. A., Khan, A. I., Abuzainah, B., & Mohammed, L. (2022). Statins and Antidepressants: A Comprehensive Review and Clinical Outlook of the Risks and Benefits of Co-prescription (2022). Cureus, 14(12). https://doi.org/10.7759/cureus.32331
• Eyles, E., Margelyte, R., Edwards, H. B., Moran, P. A., Kessler, D. S., C Davies, S. J., Bolea-Alamañac, B., Redaniel, M. T., & Sullivan, S. A. (2024). Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink. Schizophrenia Bulletin, 50(2), 447-459. https://doi.org/10.1093/schbul/sbad126
• Shah, N., Grover, S., & Rao, G. P. (2016). Clinical Practice Guidelines for Management of Bipolar Disorder. Indian Journal of Psychiatry, 59(Suppl 1), S51. https://doi.org/10.4103/0019-5545.196974
• Hafeman, D. M., Merranko, J., Liao, F., Gill, M. K., Goldstein, T. R., Diler, R., Ryan, N., Goldstein, B. I., Axelson, D. A., Strober, M., Keller, M., Hunt, J., Hower, H., Weinstock, L. M., Yen, S., & Birmaher, B. (2020). Lithium Versus Other Mood Stabilizing Medications in a Longitudinal Study of Bipolar Youth RH = Lithium in Youth With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 59(10), 1146. https://doi.org/10.1016/j.jaac.2019.06.013
• Rybakowski, J. K. (2023). Mood Stabilizers of First and Second Generation. Brain Sciences, 13(5). https://doi.org/10.3390/brainsci13050741
• Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022). Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1066988
• Ali, M. M., Taha, M. M., Ahmed, A. E., Ali, S., Baiti, M. A., Alhazmi, A. A., Alfaifi, B. A., Majrabi, R. Q., Khormi, N. Q., Hakami, A. A., Alqaari, R. A., Alhasani, R. A., & Abdelwahab, S. I. (2023). Psychotropic Medication Adherence and Its Associated Factors Among Schizophrenia Patients: Exploring the Consistency of Adherence Scales. Cureus, 15(9). https://doi.org/10.7759/cureus.46118
• Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., & Ankomah, A. (2020). Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis. Systematic Reviews, 9. https://doi.org/10.1186/s13643-020-1274-3
• Horowitz, M. A., & Moncrieff, J. (2024). Gradually tapering off antipsychotics: Lessons for practice from case studies and neurobiological principles. Current Opinion in Psychiatry, 37(4), 320-330. https://doi.org/10.1097/YCO.0000000000000940
• Rajendran, Y., Kondampati, N., Eerike, M., Mali, K., & C, L. F. (2024). A Longitudinal Analysis of Black Box Warnings: Trends and Implications for Drug Safety. Cureus, 16(4). https://doi.org/10.7759/cureus.57597
• Risks of Benzodiazepines. (2020, October 30). National Center for Health Research. https://www.center4research.org/fda-black-box-warnings-benzodiazepines-miscarriages/
• Research, C. for D. E. and. (2020). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
• Food and Drug Administration. (2018). Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications
• Yan, J. (2008). FDA Extends Black-Box Warning to All Antipsychotics. Psychiatric News, 43(14), 1–27. https://doi.org/10.1176/pn.43.14.0001
• Mok, P. L. H., Carr, M. J., Guthrie, B., Morales, D. R., Sheikh, A., Elliott, R. A., Camacho, E. M., Staa, T. van, Avery, A. J., & Ashcroft, D. M. (2024). Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ, 385, e076268. https://doi.org/10.1136/bmj-2023-076268
• DailyMed - LITHIUM CARBONATE capsule. (n.d.). Dailymed.nlm.nih.gov. Retrieved July 14, 2024, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18dc0a0c-8cee-4d20-9350-895d8de85147
• Goldenberg, M. M. (2010). Overview of Drugs Used For Epilepsy and Seizures: Etiology, Diagnosis, and Treatment. Pharmacy and Therapeutics, 35(7), 392-415. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912003/
• Research, C. for D. E. and. (2023). FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updating-warnings-improve-safe-use-prescription-stimulants-used-treat-adhd-and-other-conditions

Update history